

# Candida auris Surveillance Report


## January 6, 2025




Michigan *C. auris* Case Count: Total Cases Clinical Case Screening Case  
**1347** **336** **1011**

Cases initially identified as screening cases that later develop a positive clinical culture will solely be reported as a clinical case to avoid double counting the same individuals.  
 123 individuals converted from a screening to clinical case.

**Fig 1. Candida auris Cases in Michigan by Case Type<sup>a</sup>, 2021 – January 6, 2025**




**Fig 2. Jurisdiction of Health Care Facility at C. auris Case Detection<sup>b</sup>**




9 cases reported from out-of-state facilities.

**Fig. 3. *C. auris* Cases by Health Care Facility Type<sup>c</sup> at Detection<sup>b</sup>**




**Fig 4. Clinical *C. auris* Cases by Specimen Source, n= 336**




**Fig 5. Clinical Isolate Antifungal Susceptibility Testing<sup>d</sup>, n = 292**

Antifungal Drug	MIC <sub>50</sub> (Range)	% Resistant
Amphotericin B	1 (0.25-3)	0.3
Anidulafungin	0.5 (0.03-4)	3.4 <sup>e</sup>
Micafungin	0.25 (0.03-4)	2.4
Fluconazole	128 (4 ->256)	99.0
Itraconazole	1 (0.12-2)	NA
Isavuconazole	2 (0.03-4)	NA
Posaconazole	0.25 (0.03-1)	NA
Voriconazole	1 (0.03-8)	NA


**Fig 6. *C. auris* Cases by Race, as of Dec 31, 2024**



**Fig 7. *C. auris* Cases by Sex, as of Dec 31, 2024**



**Fig 8. *C. auris* Cases by Age, as of Dec 31, 2024**



<sup>a</sup> **Case Type:** Clinical Case – *C. auris* identified in a specimen collected during the course of clinical care for the purpose of diagnosis or treatment of disease, such as from a blood, urine, respiratory, wound; Screening Case – *C. auris* identified in a sample collected to detect colonization, such as the axilla and/or groin; *Individuals initially identified as a screening case but whom later develop a positive clinical culture will solely be reported as a clinical case in this report thereafter.*

<sup>b</sup> **Location at Detection** – Health care facility where the individual was present at the time the *C. auris* positive specimen was collected, which may or may not reflect the location where *C. auris* was acquired.

<sup>c</sup> **Health Care Facility Type:** LTACH – long-term acute care hospital; ACH – acute care hospital; vSNF – ventilator-capable skilled nursing facility; IRF – inpatient rehabilitation facility; SNF – skilled nursing facility; OP – outpatient setting.

<sup>d</sup> **Antifungal Susceptibility Testing:** Performed by the CDC Antimicrobial Resistance Laboratory Network. There are currently no established *C. auris*-specific susceptibility breakpoints. Therefore, breakpoints are defined based on those established for closely related *Candida* species and on expert opinion. [Antifungal Susceptibility Testing for \*C. auris\* | \*Candida auris\* \(\*C. auris\*\) | CDC](#)

<sup>e</sup> **Echinocandin Resistance:** *C. auris* isolates demonstrating echinocandin resistance include 4 isolates in 2022, 2 isolates in 2023, and 8 isolates in 2024. An echinocandin drug continues to be the recommended initial therapy for treatment of *C. auris* infections. [Clinical Treatment of \*C. auris\* infections | \*Candida auris\* \(\*C. auris\*\) | CDC](#)  
**MDHHS, Multidrug Resistant Organism (MDRO) Containment Unit updates *C. auris* data weekly. Monthly updates are provided for demographics including age, sex, and race data.**